Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study-Reference-Cited by-同舟云学术

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Published:2008-10 Issue:9648 Volume:372 Page:1463-1472
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Kappos Ludwig,Gold Ralf,Miller David H,MacManus David G,Havrdova Eva,Limmroth Volker,Polman Chris H,Schmierer Klaus,Yousry Tarek A,Yang Minhua,Eraksoy Mefkûre,Meluzinova Eva,Rektor Ivan,Dawson Katherine T,Sandrock Alfred W,O'Neill Gilmore N

Publisher

Elsevier BV

Subject

General Medicine

Reference36 articles.

1. Activation of Nrf2 and modulation of disease progression in EAE models by BG00012 (dimethyl fumarate) suggests a novel mechanism of action combining anti-inflammatory and neuroprotective modalities;Lukashev;Mult Scler,2007

2. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements;Itoh;Biochem Biophys Res Commun,1997

3. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes;Venugopal;Oncogene,1998

4. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression;Chen;Am J Physiol Heart Circ Physiol,2006

5. Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2;Calabrese;J Neurosci Res,2005

Cited by 409 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-01-04

2. Disease-modifying therapies;Clinical Aspects of Multiple Sclerosis Essentials and Current Updates;2024

3. Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-11-30

4. The Inhibition of Neuropathic Pain Incited by Nerve Injury and Accompanying Mood Disorders by New Heme Oxygenase-1 Inducers: Mechanisms Implicated;Antioxidants;2023-10-13

5. Disease‐modifying therapies in multiple sclerosis: A focused review of rituximab;Basic & Clinical Pharmacology & Toxicology;2023-09-20